Found: 5
Select item for more details and to access through your institution.
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10663-2
- By:
- Publication type:
- Article
Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol.
- Published in:
- Oncologist, 2024, v. 29, n. 5, p. 431, doi. 10.1093/oncolo/oyad320
- By:
- Publication type:
- Article
Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions.
- Published in:
- Oncologist, 2023, v. 28, n. 7, p. e493, doi. 10.1093/oncolo/oyad092
- By:
- Publication type:
- Article
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.
- Published in:
- Journal of Pathology, 2024, v. 263, n. 3, p. 288, doi. 10.1002/path.6279
- By:
- Publication type:
- Article
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D‐CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
- Published in:
- International Journal of Cancer, 2023, v. 153, n. 7, p. 1413, doi. 10.1002/ijc.34649
- By:
- Publication type:
- Article